Semaglutide (Wegovy) vs Semaglutide (Wegovy tablets)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

Semaglutide (Wegovy)

Marketed by Novo Nordisk

Approved in Obesitypeptide
Reliable signal

NCT03548935 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 1,961 participants. At week 68, mean body-weight change was -15.6% with semaglutide versus -2.8% with placebo, and the primary comparison was statistically significant (p<0.0001), supporting strong evidence for this clinical weight-loss endpoint.

Next expected readout: December 2026 · NCT05173714 (registry estimate)

Reported efficacy

Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801 (met)

Result source: NCT03574597

Semaglutide (Wegovy tablets)

Marketed by Novo Nordisk

Approved in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07225816 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSemaglutide (Wegovy)Semaglutide (Wegovy tablets)
Body weight, % change-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249
-14.9% vs -1.5%−13.4 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -15.8% vs -2.2% 50 mg once daily · wk 68 · n 317 · Phase 3 · primary NCT05035095
  • -14.4% vs -2.5% 25 mg once daily · wk 64 · n 192 · Phase 3 · primary NCT05564117
Weight loss of 5% or more87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
—Not posted · NCT05890976
Weight loss of 10% or more70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711
—Not posted · NCT05890976
Waist circumference, change (cm)-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013
-11.2 vs -1.4−9.8 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -13.4 vs -2.8 50 mg once daily · wk 68 · n 317 · Phase 3 · secondary NCT05035095
  • -12.9 vs -3.1 25 mg once daily · wk 64 · n 191 · Phase 3 · secondary NCT05564117

Body weight, % change

Semaglutide (Wegovy)
-19.5% vs -3.8%−15.7 vs placebo7.2 mg · wk 72 · n 950NCT05646706
28 other results
  • -14.2% vs -2.5% 2.4 mg · wk 68 · n 253 · Phase 3 · primary NCT05064735
  • -13.4% vs -1.9% 2.4 mg · wk 68 · n 193 · Phase 3 · primary NCT03811574
  • -14.4% vs -2.7% 2.4 mg · wk 52 · n 129 · Phase 3 · primary NCT05040971
  • -13.9% vs -2.5% 2.4 mg · wk 52 · n 246 · Phase 3 · primary NCT04788511
  • -12.2% vs -2.2% 2.4 mg · wk 44 · n 159 · Phase 3 · primary NCT06041217
  • -12.5% vs -3.6% 2.4 mg · wk 44 · n 238 · Phase 3 · primary NCT04251156
  • -9.9% vs -1.9% 1.7 mg · wk 68 · n 98 · Phase 3 · primary NCT03811574
  • -16.4% vs -2.6% wk 44 · n 100 · Phase 3 · primary NCT04998136
  • -16.4% vs -2.7% wk 44 · n 96 · Phase 3 · primary NCT04998136
  • -16.4% vs -6.4% 2.4 mg · wk 68 · n 117 · Phase 3 · primary NCT04074161
  • -9.4% vs -0.9% wk 104 · n 7474 · Phase 3 · secondary NCT03574597
  • -17.7% vs -5.4% 2.4 mg · wk 68 · n 520 · Phase 3 · secondary NCT03548987
  • -7.8% vs -6% 2.4 mg · wk 8 · n 396 · Phase 3 · secondary NCT03611582
  • -14.8% vs 2.3% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -16.4% vs -1.6% 2.4 mg · wk 68 · n 117 · Phase 3 · secondary NCT04074161
  • -15.8% vs -3.3% 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.9% vs -7.2% 2.4 mg · wk 68 · n 388 · Phase 3 · secondary NCT03552757
  • -19.5% vs -16.4% 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -5.5% vs -3.1% 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · primary NCT04969939
  • -13.8% vs -2.3% 0.4 mg · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -16.3% vs -2.3% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · primary NCT02453711
  • -11.2% vs -2.3% 0.3 mg · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.4% vs -2.3% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · primary NCT02453711
  • -11.6% vs -2.3% 0.2 mg · wk 52 · n 94 · Phase 2 · primary NCT02453711
  • -8.6% vs -2.3% 0.1 mg · wk 52 · n 96 · Phase 2 · primary NCT02453711
  • -6.0% vs -2.3% 0.05 mg · wk 52 · n 92 · Phase 2 · primary NCT02453711
  • -4.5% vs -0.2% wk 12 · n 43 · Phase 1 · secondary NCT04779697
  • -13.6% vs -7.4% 2.4 mg · wk 52 · n 207 · Phase 4 · secondary NCT05579249
Semaglutide (Wegovy tablets)
-14.9% vs -1.5%−13.4 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -15.8% vs -2.2% 50 mg once daily · wk 68 · n 317 · Phase 3 · primary NCT05035095
  • -14.4% vs -2.5% 25 mg once daily · wk 64 · n 192 · Phase 3 · primary NCT05564117

Weight loss of 5% or more

Semaglutide (Wegovy)
87% vs 29.2%+57.8 vs placebo2.4 mg · wk 68 · n 253NCT05064735
1 other result
  • 72.5% vs 17.7% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
Semaglutide (Wegovy tablets)
—Not posted · NCT05890976

Weight loss of 10% or more

Semaglutide (Wegovy)
70.4% vs 9.2%+61.2 vs placebo2.4 mg · wk 68 · n 253NCT05064735
9 other results
  • 61.8% vs 8.1% 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • 65.9% vs 9.5% 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • 64.6% vs 10.1% 0.4 mg · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 71.9% vs 10.1% 0.4 mg (Fast Escalation) · wk 52 · n 100 · Phase 2 · secondary NCT02453711
  • 57.8% vs 10.1% 0.3 mg · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 58.5% vs 10.1% 0.3 mg (Fast Escalation) · wk 52 · n 95 · Phase 2 · secondary NCT02453711
  • 56.0% vs 10.1% 0.2 mg · wk 52 · n 94 · Phase 2 · secondary NCT02453711
  • 36.6% vs 10.1% 0.1 mg · wk 52 · n 96 · Phase 2 · secondary NCT02453711
  • 18.9% vs 10.1% 0.05 mg · wk 52 · n 92 · Phase 2 · secondary NCT02453711
Semaglutide (Wegovy tablets)
—Not posted · NCT05890976

Waist circumference, change (cm)

Semaglutide (Wegovy)
-7.5 vs -1−6.5 vs placebowk 104 · n 7373NCT03574597
35 other results
  • -14.1 vs -4.4 2.4 mg weekly · wk 68 · n 1210 · Phase 3 · secondary NCT03548935
  • -6.9 vs 3.2 2.4 mg · wk 68 · n 518 · Phase 3 · secondary NCT03548987
  • -9.7 vs -4.3 2.4 mg · wk 68 · n 387 · Phase 3 · secondary NCT03552757
  • -15.2 vs -6.1 2.4 mg · wk 68 · n 371 · Phase 3 · secondary NCT03611582
  • -18 vs -5.6 7.2 mg · wk 72 · n 950 · Phase 3 · secondary NCT05646706
  • -13.3 vs -5.9 2.4 mg · wk 68 · n 253 · Phase 3 · secondary NCT05064735
  • -12.7 vs -0.5 2.4 mg · wk 68 · n 131 · Phase 3 · secondary NCT04102189
  • -13.6 vs -2 2.4 mg · wk 68 · n 114 · Phase 3 · secondary NCT04074161
  • -11.2 vs -1.8 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -10.2 vs -1.9 2.4 mg · wk 68 · n 193 · Phase 3 · secondary NCT03811574
  • -11.6 vs -2.8 2.4 mg · wk 52 · n 129 · Phase 3 · secondary NCT05040971
  • -12 vs -2.8 2.4 mg · wk 52 · n 246 · Phase 3 · secondary NCT04788511
  • -14.3 vs -4.5 2.4 mg · wk 52 · n 149 · Phase 3 · secondary NCT03693430
  • -9.1 vs -2.4 2.4 mg · wk 44 · n 159 · Phase 3 · secondary NCT06041217
  • -11.1 vs -3.8 2.4 mg · wk 44 · n 238 · Phase 3 · secondary NCT04251156
  • -15.2 vs -4.3 2.4 mg · wk 104 · n 143 · Phase 3 · secondary NCT03693430
  • -7.8 vs -1.8 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -7.6 vs -1.9 1.7 mg · wk 68 · n 98 · Phase 3 · secondary NCT03811574
  • -12 vs -3 wk 44 · n 100 · Phase 3 · secondary NCT04998136
  • -4.8 vs -2.7 1.0 mg + 2.4 mg · wk 48 · n 44 · Phase 2 · secondary NCT04969939
  • -12.3 vs -3.5 0.4 mg · wk 52 · n 82 · Phase 2 · secondary NCT02453711
  • -14.9 vs -3.5 0.4 mg (Fast Escalation) · wk 52 · n 91 · Phase 2 · secondary NCT02453711
  • -10.9 vs -3.5 0.3 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -11.1 vs -3.5 0.3 mg (Fast Escalation) · wk 52 · n 73 · Phase 2 · secondary NCT02453711
  • -11.0 vs -3.5 0.2 mg · wk 52 · n 87 · Phase 2 · secondary NCT02453711
  • -8.8 vs -3.5 0.1 mg · wk 52 · n 88 · Phase 2 · secondary NCT02453711
  • -6.1 vs -3.5 0.05 mg · wk 52 · n 77 · Phase 2 · secondary NCT02453711
  • -18.2 vs -14.7 30 mg/kg + 1.0 mg · wk 72 · n 42 · Phase 2 · secondary NCT05616013
  • -21.3 vs -14.7 30 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -15.8 vs -13.6 30 mg/kg + 1.0 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -19.0 vs -13.6 30 mg/kg + 2.4 mg · wk 48 · n 43 · Phase 2 · secondary NCT05616013
  • -15.6 vs -14.7 10 mg/kg + 1.0 mg · wk 72 · n 34 · Phase 2 · secondary NCT05616013
  • -18.1 vs -14.7 10 mg/kg + 2.4 mg · wk 72 · n 39 · Phase 2 · secondary NCT05616013
  • -14.6 vs -13.6 10 mg/kg + 1.0 mg · wk 48 · n 41 · Phase 2 · secondary NCT05616013
  • -16.6 vs -13.6 10 mg/kg + 2.4 mg · wk 48 · n 39 · Phase 2 · secondary NCT05616013
Semaglutide (Wegovy tablets)
-11.2 vs -1.4−9.8 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -13.4 vs -2.8 50 mg once daily · wk 68 · n 317 · Phase 3 · secondary NCT05035095
  • -12.9 vs -3.1 25 mg once daily · wk 64 · n 191 · Phase 3 · secondary NCT05564117
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
25 other shared endpoints and safety

Coverage. Semaglutide (Wegovy): 29 of 29 rows · Semaglutide (Wegovy tablets): 28 of 29 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSemaglutide (Wegovy)
Rows use multiple source trials
Semaglutide (Wegovy tablets)
Rows use multiple source trials
BMI
absolute change · kg
-5.8 vs -1 placebo kg @ 68wk2.4 mg weeklya,b
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
6 other source trials
-2.7 vs 2 placebo kg @ 68wk2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
-3.6 vs -1.2 placebo kg @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-6.2 vs -2.2 placebo kg @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-5.9 vs 0 placebo kg @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
-3.1 vs -0.6 placebo kg @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-4.3 vs -0.6 placebo kg @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-4.89 vs -0.47 placebo kg @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-5.9 vs -0.9 placebo kg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
CRP Change mg/dL
absolute change · ratio
0.38 vs 0.89 placebo ratio @ 72wk7.2 mga,b,c
NCT05646706 · Phase 3 · registry result, not featured evidence
0.42 vs 0.85 placebo ratio @ 68wk50 mg once dailya,b,c
NCT05035095 · Phase 3 · registry result, not featured evidence
DBP
absolute change · mmHg
-2 vs -1 placebo mmHg @ 68wk2.4 mgd,b
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
5 other source trials
-3 vs -1 placebo mmHg @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-2 vs -1 placebo mmHg @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
-5 vs 1 placebo mmHg @ 68wk2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
-5 vs -3 placebo mmHg @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-5 vs -3 placebo mmHg @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-6 vs -1 placebo mmHg @ 68wk50 mgd,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-2 vs -1 placebo mmHg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
-0.5 vs 0.1 placebo mmol/L @ 104wk2.4 mge,a,b,f
NCT03693430 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.46 vs 0.1 placebo mmol/L @ 104wk*2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -8.3 mg/dL as posted
-0.41 vs 0.01 placebo mmol/L @ 64wk*25 mg once dailya,b,f
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.3 mg/dL as posted
Fasting Plasma Glucose Change mg/dL
absolute change · mg
-9.2 vs -0.4 placebo mg @ 68wk2.4 mg weeklya,b
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
4 other source trials
-37.9 vs -2.3 placebo mg @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-7.3 vs -1.1 placebo mg @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-18.3 vs 1.7 placebo mg @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-19.3 vs 1.7 placebo mg @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-10.3 vs -1.8 placebo mg @ 68wk50 mg once dailya,b
NCT05035095 · Phase 3 · registry result, not featured evidence
Fasting Serum Insulin
absolute change · ratio
0.68 vs 0.84 placebo ratio @ 68wk2.4 mga,b
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
0.67 vs 0.94 placebo ratio @ 68wk50 mg once dailya,b
NCT05035095 · Phase 3 · registry result, not featured evidence
Free Fatty Acids
absolute change · ratio
0.86 vs 1.08 placebo ratio @ 68wk2.4 mga,b
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
2 other source trials
1.04 vs 1.28 placebo ratio @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.96 vs 1.28 placebo ratio @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.87 vs 1 placebo ratio @ 68wk50 mg once dailya,b
NCT05035095 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
-0.5% (n=1197) vs -0.2% (n=563) placebo @ 68wk2.4 mg weeklya,b
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
6 other source trials
-0.2% (n=515) vs 0.1% (n=246) placebo @ 68wk2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
-1.7% (n=381) vs -0.3% (n=374) placebo @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-0.5% (n=369) vs -0.3% (n=184) placebo @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-0.4% (n=126) vs -0.1% (n=59) placebo @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
-0.9% (n=98) vs 0% (n=100) placebo @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-1% (n=193) vs 0% (n=100) placebo @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-0.8% (n=126) vs 0% (n=64) placebo @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-0.2% (n=311) vs 0.1% (n=286) placebo @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
HDL-C
absolute change · ratio
1.18 vs 1.18 placebo ratio @ 68wk2.4 mga,b
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
6 other source trials
1.07 vs 1.04 placebo ratio @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
1.06 vs 1.05 placebo ratio @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
1.08 vs 1.03 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
1.08 vs 1.03 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
1.06 vs 1.06 placebo ratio @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
1.08 vs 1.06 placebo ratio @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
1.07 vs 1.03 placebo ratio @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
1.05 vs 1.01 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
IWQOL-Lite-CT Physical Function
absolute change · score
11.4 vs 4.9 placebo score @ 68wk2.4 mgd,b
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
7.6 vs 1.9 placebo score @ 68wk50 mgd,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
14.5 vs 5 placebo score @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
IWQOL-Lite-CT Physical Function
responder rate · % of participants
25.5% (n=192) vs 11% (n=100) placebo @ 68wk*2.4 mge,a,b
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 49 Participants as posted
show 1 more dose
19.4% (n=98) vs 11% (n=100) placebo @ 68wk*1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted
50% (n=298) vs 31.3% (n=278) placebo @ 68wk*50 mg once dailya,b
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted
LDL-C
absolute change · ratio
1.01 vs 1.07 placebo ratio @ 68wk2.4 mga,b
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
6 other source trials
1 vs 1 placebo ratio @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
0.96 vs 1.01 placebo ratio @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
0.91 vs 0.96 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.91 vs 0.96 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.9 vs 0.95 placebo ratio @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.86 vs 0.95 placebo ratio @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.89 vs 1.02 placebo ratio @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.98 vs 1.03 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-7 vs -1 placebo mmHg @ 68wk2.4 mg weeklya,b
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
7 other source trials
0 vs 5 placebo mmHg @ 68wk2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
-4 vs 0 placebo mmHg @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-6 vs -2 placebo mmHg @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-3 vs -1 placebo mmHg @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
-7 vs 5 placebo mmHg @ 68wk2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
-12 vs -5 placebo mmHg @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-11 vs -5 placebo mmHg @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-11 vs -2 placebo mmHg @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-7 vs -1 placebo mmHg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning
absolute change · score
2.8 vs 0.8 placebo score @ 68wk2.4 mgd,b
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
1 other source trial
12.7 vs 6.4 placebo score @ 68wk2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
2.4 vs 0 placebo score @ 68wk50 mg once dailyd,b
NCT05035095 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning
responder rate · % of participants
22.4% (n=192) vs 13% (n=100) placebo @ 68wk*2.4 mge,a,b
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
show 1 more dose
19.4% (n=98) vs 13% (n=100) placebo @ 68wk*1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted
37.3% (n=303) vs 20% (n=280) placebo @ 68wk*50 mg once dailya,b
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 113 Participants as posted
Total Cholesterol
absolute change · ratio
1.05 vs 1.11 placebo ratio @ 68wk2.4 mga,b
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
6 other source trials
0.99 vs 1 placebo ratio @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
0.96 vs 1.01 placebo ratio @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
0.92 vs 0.98 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.92 vs 0.98 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.93 vs 1 placebo ratio @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.91 vs 1 placebo ratio @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.92 vs 1.02 placebo ratio @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.97 vs 1.01 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Triglycerides
absolute change · ratio
0.94 vs 1.12 placebo ratio @ 68wk2.4 mga,b
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
6 other source trials
0.79 vs 0.92 placebo ratio @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
0.77 vs 0.91 placebo ratio @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
0.71 vs 1.04 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.71 vs 1.04 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.78 vs 1.05 placebo ratio @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.79 vs 1.05 placebo ratio @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.73 vs 0.99 placebo ratio @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.77 vs 0.96 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
VAT Change Cm2
absolute change · cm
-67.4 vs -13.8 placebo cm @ 68wk2.4 mge,a,b
NCT03811574 · Phase 3 · registry result, not featured evidence
show 1 more dose
-41.7 vs -13.8 placebo cm @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-0.06 vs 0.02 placebo cm @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
Visceral Fat
percent change · % of baseline
-41% (n=86) vs -7.1% (n=43) placebo @ 68wk2.4 mge,a,b
NCT03811574 · Phase 3 · registry result, not featured evidence
show 1 more dose
-22.3% (n=45) vs -7.1% (n=43) placebo @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-35.1% (n=50) vs 0.6% (n=20) placebo @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
VLDL-C
absolute change · ratio
0.94 vs 1.12 placebo ratio @ 68wk2.4 mga,b
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
6 other source trials
0.8 vs 0.92 placebo ratio @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
0.77 vs 0.91 placebo ratio @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
0.71 vs 1.03 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.71 vs 1.03 placebo ratio @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
0.79 vs 1.05 placebo ratio @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.79 vs 1.05 placebo ratio @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
0.74 vs 0.99 placebo ratio @ 68wk50 mga,b
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.77 vs 0.96 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
-16.1 vs -2.9 placebo kg @ 68wk2.4 mg weeklya,b
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
7 other source trials
-7.5 vs 5.7 placebo kg @ 68wk2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
-9.9 vs -3.4 placebo kg @ 68wk2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-17.5 vs -6.2 placebo kg @ 68wk2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-15.7 vs 2.3 placebo kg @ 68wk2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
-15.8 vs -1.4 placebo kg @ 68wk2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
-8.3 vs -1.7 placebo kg @ 68wk1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-11.3 vs -1.7 placebo kg @ 68wk2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
-16.1 vs -2.4 placebo kg @ 68wk50 mg once dailya,b
NCT05035095 · Phase 3 · registry result, not featured evidence
Weight Loss 10%
event count · % of participants
69.1% (n=1212) vs 12% (n=577) placebo @ 68wk*2.4 mg weeklya,b
Yes
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 838 Participants as posted
6 other source trials
79% (n=520) vs 20.4% (n=250) placebo @ 68wk*2.4 mg
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 411 Participants as posted
45.6% (n=388) vs 8.2% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 177 Participants as posted
75.3% (n=373) vs 27% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 281 Participants as posted
70.9% (n=117) vs 15.4% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
41.8% (n=98) vs 5% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
60.6% (n=193) vs 5% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 117 Participants as posted
65.4% (n=127) vs 9.4% (n=64) placebo @ 68wk*50 mga,b
Yes
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
1 other source trial
69.4% (n=317) vs 11.9% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 220 Participants as posted
Weight Loss 15%
event count · % of participants
50.5% (n=1212) vs 4.9% (n=577) placebo @ 68wk*2.4 mg weeklya,b
Yes
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 612 Participants as posted
6 other source trials
63.7% (n=520) vs 9.2% (n=250) placebo @ 68wk*2.4 mg
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 331 Participants as posted
25.8% (n=388) vs 3.2% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 100 Participants as posted
55.8% (n=373) vs 13.2% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 208 Participants as posted
55.6% (n=117) vs 6.4% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 65 Participants as posted
24.5% (n=98) vs 3% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
40.9% (n=193) vs 3% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 79 Participants as posted
47.2% (n=127) vs 0% (n=64) placebo @ 68wk*50 mga,b
Yes
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 60 Participants as posted
1 other source trial
53.6% (n=317) vs 5.8% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 170 Participants as posted
Weight Loss 20%
event count · % of participants
32% (n=1212) vs 1.7% (n=577) placebo @ 68wk*2.4 mg weeklya,b
Yes
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 388 Participants as posted
5 other source trials
13.1% (n=388) vs 1.6% (n=376) placebo @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 51 Participants as posted
35.7% (n=373) vs 3.7% (n=189) placebo @ 68wk*2.4 mg
Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 133 Participants as posted
38.5% (n=117) vs 2.6% (n=78) placebo @ 68wk*2.4 mg
Yes
NCT04074161 · Phase 3 · registry result, not featured evidence · converted to % from 45 Participants as posted
11.2% (n=98) vs 2% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 11 Participants as posted
19.7% (n=193) vs 2% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 38 Participants as posted
32.3% (n=127) vs 0% (n=64) placebo @ 68wk*50 mga,b
Yes
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
1 other source trial
33.8% (n=317) vs 2.7% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
Weight Loss 5%
event count · % of participants
88.7% (n=520) vs 47.6% (n=250) placebo @ 68wk*2.4 mga,b
Yes
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 461 Participants as posted
3 other source trials
68.8% (n=388) vs 57.1% (n=380) Semaglutide 1.0 mg @ 68wk*2.4 mg
Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 267 Participants as posted
72.4% (n=98) vs 21% (n=100) placebo @ 68wk*1.7 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 71 Participants as posted
82.9% (n=193) vs 21% (n=100) placebo @ 68wk*2.4 mg
Yes
NCT03811574 · Phase 3 · registry result, not featured evidence · converted to % from 160 Participants as posted
84.3% (n=127) vs 17.2% (n=64) placebo @ 68wk*50 mga,b
Yes
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
1 other source trial
84.9% (n=317) vs 25.8% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 269 Participants as posted
Dropout rate
—2.4 mg weeklyg
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
5.1%2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
11%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
3.2%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
2.9%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
16.7%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
15.3%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
14.4%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
0%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
4.6%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
0%
NCT04998136 · Phase 3 · registry result, not featured evidence
9.2%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
7.2%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
2.7%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
1.5%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
4.8%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
2.6%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
2%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
2%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
33.9%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
38.6%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
50%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
37.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%
NCT05302596 · Phase 2 · registry result, not featured evidence
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.9%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
8.7%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.9%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.7%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
10.4%
NCT04779697 · Phase 1 · registry result, not featured evidence
4.4%25 mg once dailyh
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
3%50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
4.2%50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—2.4 mg weeklyg
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
5.3%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
—
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
6.4%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
—Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
—Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
—
NCT04998136 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
—1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
1.8%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.3%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
5.4%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
—
NCT05302596 · Phase 2 · registry result, not featured evidence
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
—0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
—
NCT04779697 · Phase 1 · registry result, not featured evidence
—25 mg once dailyh
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
—50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Serious AEs
9.8%2.4 mg weeklyg
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 40 more results
—2.4 mg weekly
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
—2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
7.7%2.4 mg
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
9.9%2.4 mg
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
33.4%
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
9.1%2.4 mg
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
4.2%Behavioral Treatment + Medication
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
0%Continued Medication (Semaglutide)
NCT05548647 · Phase 4 · registry result, not featured evidence
1.2%2.4 mg
NCT05579249 · Phase 4 · registry result, not featured evidence
8.1%2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT06041217 · Phase 3 · registry result, not featured evidence
7.3%7.2 mg
NCT05646706 · Phase 3 · registry result, not featured evidence
12.9%
NCT04998136 · Phase 3 · registry result, not featured evidence
10%2.4 mg
NCT05064735 · Phase 3 · registry result, not featured evidence
8.7%2.4 mg
NCT05040971 · Phase 3 · registry result, not featured evidence
13.3%2.4 mg
NCT04788511 · Phase 3 · registry result, not featured evidence
5.6%2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
—2.4 mg
NCT04251156 · Phase 3 · registry result, not featured evidence
11.3%2.4 mg
NCT04102189 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT04074161 · Phase 3 · registry result, not featured evidence
7.9%2.4 mg
NCT03693430 · Phase 3 · registry result, not featured evidence
5%2.4 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
7%1.7 mg
NCT03811574 · Phase 3 · registry result, not featured evidence
10.7%30 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.7%30 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
12.5%10 mg/kg + 1.0 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
14.5%10 mg/kg + 2.4 mg
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
0%
NCT05302596 · Phase 2 · registry result, not featured evidence
12.5%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%2.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
4.3%1.0 mg + 2.4 mg
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
12.7%0.4 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
6.8%0.4 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
5.8%0.3 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
5.9%0.3 mg (Fast Escalation)
NCT02453711 · Phase 2 · registry result, not featured evidence
4.9%0.2 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
7.8%0.1 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
12.6%0.05 mg
NCT02453711 · Phase 2 · registry result, not featured evidence
2.1%
NCT04779697 · Phase 1 · registry result, not featured evidence
3.9%25 mg once dailyh
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
6%50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
9.6%50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
2.4 mg weeklyg
nausea 44.1% (placebo 17.4%)
diarrhoea 31.5% (placebo 15.9%)
vomiting 24.6% (placebo 6.6%)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
2.4 mg
diarrhoea 14.4% (placebo 7.1%)
nausea 14% (placebo 4.9%)
constipation 11.6% (placebo 6%)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 33.5% (placebo 9.2%)
diarrhoea 21.3% (placebo 11.9%)
vomiting 21.3% (placebo 2.7%)
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
covid-19 20.3% (placebo 20.3%)
nausea 18.1% (placebo 3.8%)
diarrhoea 10.6% (placebo 4%)
NCT03574597 · Phase 3 · monotherapy · Obesity · phase 3
2.4 mg
nausea 58.2% (placebo 22.1%)
constipation 36.9% (placebo 24.5%)
diarrhoea 36.1% (placebo 22.1%)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
nausea 73.6% (placebo 25%)
constipation 52.8% (placebo 16.7%)
diarrhea 37.5% (placebo 22.9%)
NCT05548647 · Phase 4 · registry result, not featured evidence · combination
diarrhea 20% (placebo 22.9%)
constipation 10% (placebo 16.7%)
eructation 10% (placebo 6.3%)
NCT05548647 · Phase 4 · registry result, not featured evidence
2.4 mg
decreased appetite 19.3% (placebo 2.5%)
diarrhoea 18.6% (placebo 7.4%)
nausea 18% (placebo 2.5%)
NCT06041217 · Phase 3 · registry result, not featured evidence
7.2 mg
nausea 43.7% (placebo 13.4%)
diarrhoea 27.3% (placebo 12.9%)
vomiting 24.8% (placebo 7%)
NCT05646706 · Phase 3 · registry result, not featured evidence
nausea 37.6% (placebo 14.3%)
diarrhoea 27.7% (placebo 6.1%)
constipation 21.8% (placebo 16.3%)
NCT04998136 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 21.9% (placebo 8.9%)
covid-19 18.6% (placebo 22.2%)
constipation 11.9% (placebo 5.2%)
NCT05064735 · Phase 3 · registry result, not featured evidence
2.4 mg
covid-19 34.8% (placebo 30.4%)
nausea 29% (placebo 4.3%)
constipation 18.1% (placebo 0%)
NCT05040971 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 17.1% (placebo 2.6%)
covid-19 13.7% (placebo 15.4%)
diarrhoea 9.1% (placebo 3.8%)
NCT04788511 · Phase 3 · registry result, not featured evidence
2.4 mg
diarrhoea 26.1% (placebo 10.3%)
nausea 24.1% (placebo 7.1%)
upper respiratory tract infection 20.5% (placebo 20.6%)
NCT04251156 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 42.1% (placebo 17.9%)
vomiting 36.1% (placebo 10.4%)
diarrhoea 21.8% (placebo 19.4%)
NCT04102189 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 61.1% (placebo 22.4%)
constipation 38.9% (placebo 23.5%)
diarrhoea 27.8% (placebo 25.9%)
NCT04074161 · Phase 3 · registry result, not featured evidence
2.4 mg
nausea 53.3% (placebo 21.7%)
diarrhoea 34.9% (placebo 23.7%)
constipation 30.9% (placebo 11.2%)
NCT03693430 · Phase 3 · registry result, not featured evidence
2.4 mg
nasopharyngitis 26.6% (placebo 17.8%)
constipation 26.1% (placebo 3%)
nausea 17.6% (placebo 4%)
NCT03811574 · Phase 3 · registry result, not featured evidence
1.7 mg
nasopharyngitis 24% (placebo 17.8%)
diarrhoea 22% (placebo 5.9%)
constipation 19% (placebo 3%)
NCT03811574 · Phase 3 · registry result, not featured evidence
30 mg/kg + 1.0 mg
muscle spasms 64.3%
acne 55.4%
diarrhoea 44.6%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
30 mg/kg + 2.4 mg
muscle spasms 63.6%
acne 52.7%
diarrhoea 49.1%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 1.0 mg
muscle spasms 57.1%
diarrhoea 48.2%
acne 42.9%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
10 mg/kg + 2.4 mg
muscle spasms 65.5%
nausea 61.8%
diarrhoea 52.7%
NCT05616013 · Phase 2 · registry result, not featured evidence · combination · Obesity · phase 2
gastrointestinal side effects: constipation 57.1%
gi side effects: nausea 28.6%
gi side effects: vomiting 14.3%
NCT05302596 · Phase 2 · registry result, not featured evidence
2.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 87.5% (placebo 12.5%)
vomiting 75% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
2.0 mg + 2.4 mg
nausea 62.5% (placebo 12.5%)
constipation 50% (placebo 0%)
vomiting 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
decreased appetite 87.5% (placebo 75%)
nausea 50% (placebo 12.5%)
abdominal pain 37.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
1.0 mg + 2.4 mg
nausea 44.7% (placebo 12.5%)
vomiting 31.9% (placebo 0%)
constipation 25.5% (placebo 0%)
NCT04969939 · Phase 2 · registry result, not featured evidence · combination
0.4 mg
nausea 48% (placebo 17.6%)
diarrhoea 37.3% (placebo 11.8%)
constipation 23.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.4 mg (Fast Escalation)
nausea 48.5% (placebo 17.6%)
constipation 28.2% (placebo 4.4%)
diarrhoea 27.2% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg
nausea 41.7% (placebo 17.6%)
diarrhoea 26.2% (placebo 11.8%)
constipation 17.5% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.3 mg (Fast Escalation)
nausea 53.9% (placebo 17.6%)
diarrhoea 27.5% (placebo 11.8%)
vomiting 20.6% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.2 mg
nausea 43.7% (placebo 17.6%)
diarrhoea 34% (placebo 11.8%)
constipation 25.2% (placebo 4.4%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.1 mg
nausea 41.2% (placebo 17.6%)
diarrhoea 24.5% (placebo 11.8%)
nasopharyngitis 22.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
0.05 mg
nausea 31.1% (placebo 17.6%)
diarrhoea 19.4% (placebo 11.8%)
nasopharyngitis 15.5% (placebo 11.8%)
NCT02453711 · Phase 2 · registry result, not featured evidence
nausea 58.3% (placebo 20.8%)
abdominal pain 31.3% (placebo 20.8%)
diarrhea 29.2% (placebo 10.4%)
NCT04779697 · Phase 1 · registry result, not featured evidence
25 mg once dailyh
nausea 46.6% (placebo 18.6%)
vomiting 30.9% (placebo 5.9%)
nasopharyngitis 21.1% (placebo 26.5%)
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
50 mg
covid-19 30.6% (placebo 33.3%)
nausea 25.4% (placebo 7.6%)
constipation 20.9% (placebo 9.1%)
NCT05132088 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 51.8% (placebo 15.3%)
covid-19 35.6% (placebo 34.5%)
constipation 27.5% (placebo 15%)
NCT05035095 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 72 weeks versus 68 weeks.
  4. dPopulation context differs: registered conditions differ.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fAssessment timepoints differ: 104 weeks versus 64 weeks.
  7. gPopulation comparability has not been reviewed for 30 of these studies.
  8. hPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Semaglutide (Wegovy)

Weight -15.6% (n=1306) vs -2.8% (n=655) placebo @ 68wk2.4 mg weekly
percent change · % of baseline
In-trial observation period
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 3 more results
-9.9% (n=404) vs -3.3% (n=403) placebo @ 68wk2.4 mg
In-trial observation period
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3
-16.5% (n=407) vs -5.8% (n=204) placebo @ 68wk2.4 mg
In-trial observation period
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
-15.9% (n=144) vs -1.9% (n=128) placebo @ 104wk2.4 mg
In-trial observation period
NCT03693430 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 80.2% (n=1306) vs 27.8% (n=655) placebo @ 68wk2.4 mg weekly
event count · % of participants
In-trial observation period · Yes
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 1047 Participants as posted
show 3 more results
66.1% (n=404) vs 26.6% (n=403) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03552757 · Phase 3 · monotherapy · Obesity, Type 2 Diabetes · phase 3 · converted to % from 267 Participants as posted
79.4% (n=407) vs 44.1% (n=204) placebo @ 68wk*2.4 mg
In-trial observation period · Yes
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3 · converted to % from 323 Participants as posted
77.1% (n=144) vs 34.4% (n=128) placebo @ 104wk*2.4 mg
In-trial observation period · Yes
NCT03693430 · Phase 3 · registry result, not featured evidence · converted to % from 111 Participants as posted
SF-36 Physical Functioning 2.3 vs 0.4 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in physical functioning score (SF-36)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
show 2 more results
1 vs -1.2 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03548987 · Phase 3 · monotherapy · Obesity · phase 3
2.5 vs 1.7 placebo score @ 68wk2.4 mg
Change in physical functioning score (SF-36)
NCT03611582 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 - Role Physical 1.1 vs -0.2 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (role-physical score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Bodily Pain 0.5 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (bodily pain score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 General Health 2 vs -0.6 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (general health score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Vitality 0.7 vs -1.3 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (vitality score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Social Functioning -0.3 vs -1.4 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (social functioning score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 - Role Emotional -0.9 vs -1.5 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (role-emotional score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Mental Health -0.8 vs -1.7 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (mental health score)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Physical Component Summary 2.4 vs 0.2 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (physical component summary)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3
SF-36 Mental Component Summary -1.5 vs -2.1 placebo score @ 68wk2.4 mg weekly
absolute change · score
Change in SF-36 (mental component summary)
NCT03548935 · Phase 3 · monotherapy · Obesity · phase 3

+ 119 further endpoints in the CSV export.

Semaglutide (Wegovy tablets)

BMI Less Than 30 43.9% (n=294) vs 7.1% (n=268) placebo @ 68wk50 mg once daily
event count · % of participants
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 129 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Semaglutide (Wegovy)'s landscape · Semaglutide (Wegovy tablets)'s landscape